Insulet Corporation PODD
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -45.96%
- 1 year
- -50.92%
- Open
- 150.22
- Prev close
- 149.68
- Mkt cap
- 10.65B
- Vol
- 1.77M
- Avg vol
- 1.69M
- EPS
- 5.34
- P/E
- 28.77
- Div yield
- 0.00%
More statistics
- Low
- 149.68
- High
- 154.70
- Forward P/E
- 19.89
- Beta
- 1.05
- Short ratio
- 3.51
- Inst. own
- 106.12%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 140.91
- 200-d avg
- 178.80
- 1y target
- 167.17
MAX chart
Events in this range
- Aug 7, 2025Earnings: 1.17; estimate 0.92; surprise 27.17%
- Nov 6, 2025Earnings: 1.24; estimate 1.14; surprise 8.77%
- May 6, 2026Earnings: 1.42; estimate 1.19; surprise 19.33%
- Aug 5, 2026Earnings: 1.66; estimate 1.47; surprise 12.93%
- Aug 6, 2026Rating: UBS · Neutral → Neutral
- Aug 6, 2026Rating: TD Cowen · Hold → Hold
- Aug 6, 2026Downgrade: Leerink Partners · Outperform → Market Perform
- Aug 6, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 7, 2026Rating: Barclays · — → Equal-Weight
- Nov 4, 2026Earnings: —; estimate 1.59; surprise —%
Signals (76)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Mar 1, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 1, 2026 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Sep 1, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bearish | Jul 1, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 1, 2023 | 3 years ago |
| SMA: Bullish | Jun 1, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 1, 2023 | 3 years ago |
| SMA: Bullish | Oct 1, 2022 | 4 years ago |
| SMA: Bullish | Oct 1, 2022 | 4 years ago |
| SMA: Bearish | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Sep 1, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 1, 2022 | 4 years ago |
| SMA: Bearish | Apr 1, 2022 | 4 years ago |
| SMA: Bearish | Dec 1, 2021 | 4 years ago |
Newest 20 of 76.
News
17 hours ago defenseworld.net
Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake
International Assets Investment Management LLC grew its position in Insulet Corporation (NASDAQ: PODD) by 61,543.8% during the undefined quarter, according to the company in its most recent…
5 days ago zacks.com
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago globenewswire.com
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
2 weeks ago defenseworld.net
Insulet Corporation $PODD Shares Sold by Curated Wealth Partners LLC
Curated Wealth Partners LLC lessened its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 83.4% in the third quarter, according to the company in its most recent filing with the Securities…
2 weeks ago zacks.com
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
-
3 weeks ago benzinga.com
Jefferies Maintains Buy on Insulet, Lowers Price Target to $190
Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.
3 weeks ago businesswire.com
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market…
3 weeks ago benzinga.com
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript
Insulet (NASDAQ:PODD) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
-
3 weeks ago benzinga.com
Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150
Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.
1 month ago businesswire.com
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced…
1 month ago zacks.com
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
1 month ago defenseworld.net
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet (NASDAQ: PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated…
1 month ago marketbeat.com
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated…
1 month ago seekingalpha.com
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
1 month ago businesswire.com
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will…
1 month ago defenseworld.net
California State Teachers Retirement System Has $2.22 Billion Stock Position in Insulet Corporation $PODD
California State Teachers Retirement System grew its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 13,901.9% in the undefined quarter, according to the company in its most recent…
1 month ago defenseworld.net
Insulet Corporation $PODD Stock Position Raised by Amundi
Amundi increased its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 13.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
1 month ago seekingalpha.com
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
1 month ago zacks.com
Here's Why Insulet (PODD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
1 month ago zacks.com
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
1 month ago zacks.com
Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
1 month ago zacks.com
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
1 month ago seekingalpha.com
Baron SMID Cap ETF Q2 2026 Portfolio Activity
During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market…
2 months ago benzinga.com
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
-
2 months ago benzinga.com
Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145
Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.
-
2 months ago benzinga.com
TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144
TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.
-
2 months ago benzinga.com
UBS Maintains Neutral on Insulet, Lowers Price Target to $150
UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $160
RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $245 to $160.
-
2 months ago benzinga.com
Bernstein Maintains Outperform on Insulet, Lowers Price Target to $175
Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $175.
-
2 months ago benzinga.com
Benchmark Maintains Buy on Insulet, Lowers Price Target to $185
Benchmark analyst Bruce D. Jackson maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $185.
-
2 months ago benzinga.com
Stifel Maintains Buy on Insulet, Lowers Price Target to $180
Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $225 to $180.
2 months ago benzinga.com
Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies…
2 months ago benzinga.com
This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. HUBS, PODD, FRPT, WTTR, REXR downgraded.
2 months ago benzinga.com
These Analysts Slash Their Forecasts On Insulet After Q2 Results
Insulet Corp. (NASDAQ:PODD) reported strong Q2 earnings but lowered revenue outlook for 2021. Analysts downgraded stock and lowered price targets.
-
2 months ago benzinga.com
Wells Fargo Downgrades Insulet to Equal-Weight, Lowers Price Target to $144
Wells Fargo analyst Lawrence Biegelsen downgrades Insulet (NASDAQ:PODD) from Overweight to Equal-Weight and lowers the price target from $255 to $144.
-
2 months ago benzinga.com
JP Morgan Downgrades Insulet to Neutral, Lowers Price Target to $152
JP Morgan analyst Robbie Marcus downgrades Insulet (NASDAQ:PODD) from Overweight to Neutral and lowers the price target from $275 to $152.
-
2 months ago benzinga.com
Truist Securities Downgrades Insulet to Hold, Lowers Price Target to $153
Truist Securities analyst Richard Newitter downgrades Insulet (NASDAQ:PODD) from Buy to Hold and lowers the price target from $210 to $153.
2 months ago benzinga.com
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
2 months ago benzinga.com
Omnipod Sales Soar, But Insulet's Outlook Cut Sparks Stock Selloff
Insulet (PODD) stock falls despite beating Q2 earnings as the company lowers its full-year 2026 revenue guidance. Get details here.
-
2 months ago benzinga.com
Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.43 Est; Lowers FY2026 Sales Guidance from $3.277B-$3.331B to $3.250B-$3.304B vs $3.321B Est
Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.46 vs $6.43 Est. lowers FY2026 sales outlook from $3.277 billion-$3.331 billion to $3.250 billion-$3.304 billion vs $3.321 billion estimate.
-
2 months ago benzinga.com
Insulet Q2 Adj. EPS $1.66 Beats $1.45 Estimate, Sales $801.700M Beat $787.228M Estimate
Insulet (NASDAQ:PODD) reported quarterly earnings of $1.66 per share which beat the analyst consensus estimate of $1.45 by 14.48 percent. This is a 41.88 percent increase over earnings of $1.17 per…
-
3 months ago benzinga.com
Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes
The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise,…
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210
Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245
RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $245.
-
3 months ago benzinga.com
Stifel Maintains Buy on Insulet, Lowers Price Target to $225
Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $225.
-
3 months ago benzinga.com
Citigroup Maintains Neutral on Insulet, Raises Price Target to $172
Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.
3 months ago benzinga.com
FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports
FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Insulet, Lowers Price Target to $180
Evercore ISI Group analyst Daniel Markowitz maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $180.